Dexcel Pharma

Company Overview

Snapshot

Founded in January 1965 by Dan Oren, Dexcel Pharma operates with over 500 employees. The company focuses on the discovery, development, manufacture, and commercialization of pharmaceutical products, notably securing a deal with Kitov Pharma for a hypertension drug in April 2014.

Business overview

Dexcel Pharma is a pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of innovative pharmaceutical products. Leveraging proprietary controlled-release technologies, the company develops novel formulations of existing molecules and complex generic drugs. Its core products include Omeprazole, PerioChip, and Deximune, targeting large therapeutic markets in the U.S. and the EU. Dexcel Pharma operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology, and serves patients and the broader healthcare industry.

Strategic signal

In April 2014, Dexcel Pharma signed a significant deal with Kitov Pharma for a hypertension drug. This agreement signals Dexcel Pharma's strategic engagement in commercializing its pharmaceutical developments through partnerships, indicating a focus on expanding market reach for its drug formulations.

Company Intelligence Q&A

When was Dexcel Pharma founded?

Dexcel Pharma was founded in January 1965.

Who founded Dexcel Pharma?

Dexcel Pharma was founded by Dan Oren.

What is Dexcel Pharma's primary focus?

Dexcel Pharma focuses on the discovery, development, manufacture, and commercialization of innovative pharmaceutical products using proprietary controlled-release technologies.

What significant deal did Dexcel Pharma sign in 2014?

In April 2014, Dexcel Pharma signed a deal with Kitov Pharma for a hypertension drug.

What are some of Dexcel Pharma's key products?

Dexcel Pharma's key products include Omeprazole, PerioChip, and Deximune.